HCW Biologics Inc. filings document a clinical-stage biopharmaceutical issuer developing fusion immunotherapeutics through the TOBI and TRBC platforms. Its SEC records include 8-K reports for operating results, clinical and regulatory program updates, material agreements, licensing activity and Nasdaq-related corporate events, along with registration statements covering securities offerings and related capital-structure disclosures.
HCWB proxy and governance filings describe annual meeting matters, shareholder voting procedures and bylaw amendments, including quorum provisions. The company’s formal disclosures also address product-candidate development, financial condition, emerging growth company status, risk factors, ownership and governance controls relevant to its public-company reporting profile.
HCW Biologics Inc. closed a debt financing described as providing up to $10.0 million in cash on November 4, 2026: $3.0 million was paid to the company, less $30,000 in transaction costs, and $7.0 million was deposited into an account of its wholly owned subsidiary, with access subject to conditions. Original principal was $3.2 million for the A-1 Note and $7.0 million for the B Note; the A-1 includes a $240,000 original issue discount. The company said funding would support its HCW9302 Phase 1 study in alopecia areata and establishment of a Recommended Phase 2 Dose, expected in the first quarter of 2027.
Both notes mature 24 months after issuance; annual interest is 8% on A-1 and 5% on B, with a 10% prepayment premium on each. Beginning six months after closing, the lender may redeem up to $125,000 per calendar month under A-1 plus make-whole interest, and has limited redemption rights under both notes, subject to conditions. The company’s obligations are secured by a Deposit Account Control Agreement, HCWB Sub’s guaranty and a pledge of all its membership interests. The company agreed to pay Maxim Group LLC a 7.0% cash fee on gross proceeds.
HCW Biologics Inc. reported a Rule 506(b) exempt offering with $1,500,000 USD sold and $0 USD remaining to be sold. The first sale date was September 24, 2026. The selected securities included equity, options, warrants or other rights to acquire another security, and securities to be acquired upon exercise. The notice lists $0 USD in finders’ fees.
HCW Biologics Inc. (HCWB) is registering for resale up to 1,807,228 shares of common stock issuable to Armistice Capital Master Fund Ltd. This includes 903,614 shares underlying pre-funded warrants exercisable at $0.0001 per share and 903,614 shares underlying common warrants exercisable at $1.66 per share; the common warrants are issuable only after stockholder approval under Nasdaq Listing Rule 5635(d).
The September 2026 PIPE transaction closed September 24, 2026, generating approximately $1.5 million in gross proceeds before expenses from 903,614 units sold at $1.6599 each. HCWB will receive no proceeds from resales and expects nominal proceeds from pre-funded warrant exercises; it may receive up to approximately $1.5 million if the common warrants are approved, issued and exercised for cash. A stockholder meeting is planned on or about January 26, 2027.
HCW Biologics also entered a distribution agreement granting Akron Biotech rights to distribute HCW11-006, subject to due diligence and product testing, with closing required by November 30, 2026. The company disclosed unremediated control weaknesses in long-lived-asset impairment and warrant accounting and negotiations over repayment of $740,000 owed to Cooley.
HCW Biologics is seeking stockholder approval to permit issuance of up to 618,682 shares upon exercise of Common Warrants tied to its July 29, 2026 private placement. The warrants have an exercise price of $2.585 per share, and the company reported the financing totaled $1.6 million. Without approval, the warrants would remain outstanding but could not be exercised to the extent an exercise exceeded the Exchange Cap.
The Exchange Cap is 319,370 shares, approximately 19.99% of common shares outstanding immediately before the securities purchase agreement. If approved and exercised, the warrants could result in dilution of existing holders’ economic and voting interests. The special meeting is November 17, 2026; stockholders of record on September 21, 2026 may vote. Approval requires a majority of votes cast, and the board recommends voting FOR the proposal.
HCW Biologics Inc. agreed to sell 903,614 units in a private placement at $1.6599 per unit, for approximately $1.5 million in gross proceeds before offering expenses. Each unit includes one pre-funded warrant to purchase one common share and a right to receive one common stock purchase warrant to purchase one share, subject to stockholder approval. The pre-funded warrants are immediately exercisable at $0.0001 per share and remain exercisable until exercised in full; exercise is limited so the holder’s beneficial ownership does not exceed 9.99% of common stock outstanding immediately after exercise.
If stockholders approve, HCW Biologics will issue common warrants exercisable for up to 903,614 shares at $1.66 per share. They will expire five and one-half years after issuance and carry a 4.99% beneficial ownership limit, subject to adjustment by the holder. HCW Biologics intends to use net proceeds for working capital and general corporate purposes, including clinical development activities. It also agreed to file a Form S-1 resale registration statement within 15 trading days following closing and use commercially reasonable efforts to have it declared effective within 60 days following closing.
HCW Biologics Inc. (HCWB) reported that on September 9, 2026 it filed Amendment No. 1 to its Preliminary Proxy Statement for an upcoming Special Meeting of Stockholders. After considering stockholder feedback, the board decided not to seek approval of Proposal No. 2 from the original preliminary proxy, which would have asked stockholders to approve an amended performance-based equity plan for eligible officers, directors and employees, and removed that proposal in the amendment. The amendment also changes the date of the Special Meeting, the record date for stockholders entitled to vote, and certain related dates, while making no other substantive changes to the original preliminary proxy.
HCW Biologics Inc. (HCWB) has amended its preliminary proxy statement and set a virtual special meeting for November 17, 2026 to seek stockholder approval of a single substantive item. Proposal One asks stockholders to approve, for purposes of Nasdaq Listing Rule 5635(d), the issuance of Common Warrants exercisable for up to 618,682 shares of common stock, issued in connection with a $1.6 million private placement completed on July 29, 2026, at an exercise price of $2.585 per share.
Nasdaq’s “20% Rule” currently caps issuance upon warrant exercise to 319,370 shares, approximately 19.99% of shares outstanding immediately before the Securities Purchase Agreement. Approval would permit issuance above this Exchange Cap, enabling full exercise of the Common Warrants but diluting existing holders’ voting and economic interests if exercised. If Proposal One is not approved, the Common Warrants remain outstanding but cannot be exercised above the Exchange Cap, which the company states may limit anticipated financing benefits from the offering.
The amendment also removes a prior proposal to approve an amended performance-based equity plan and updates the special meeting and record dates.
HCW Biologics Inc. (HCWB) entered into an Exclusive Distribution Agreement with Akron Biotech to commercialize its commercial-ready molecule HCW11-006 as a reagent for cell therapy manufacturing and other ex vivo applications worldwide, excluding China. The agreement has a five-year term from closing, which is subject to satisfactory due diligence and product testing and is expected to close no later than November 30, 2026.
HCW Biologics and Akron plan to enter a Supply Agreement within 60 days after closing. Assuming closing occurs, HCW Biologics will receive $200,000 at closing, $100,000 within 30 days of executing the Supply Agreement, and $100,000 on each of the first and second anniversaries of closing, plus additional quarterly payments for technical support as needed. HCW Biologics also committed to continue supplying HCW11-006 to support existing Akron customers if it terminates the agreement for convenience.
HCW Biologics Inc. (HCWB) has called an October 27, 2026 virtual special stockholder meeting to vote on two main items. First, stockholders are asked to approve, for Nasdaq Listing Rule 5635(d) purposes, the issuance of Common Warrants exercisable for up to 618,682 shares of common stock at $2.585 per share, issued in a $1.6 million private placement completed on July 29, 2026. Approval would allow potential issuance above the 19.99% “Exchange Cap” tied to that financing.
Second, HCW Biologics seeks approval of an Amended and Restated 2021 Equity Incentive Plan, adding a 2,500,000‑share Special Reserve for performance-based awards under the 2026 Special Reserve Plan and eliminating the plan’s automatic annual “evergreen” increase. As of September 1, 2026, 2,236,324 shares of common stock were outstanding and only 15,704 shares remained available under the existing plan. Special Reserve awards would be granted in 20% tranches only when the stock price reaches escalating milestones beginning at $5 per share, with vesting over one to two years, to support retention and align compensation with stockholder value. The board recommends voting FOR both proposals.